Tomohiro Nakano et al.
Biochemical and biophysical research communications, 464(4), 1084-1089 (2015-07-22)
The anti-tumor activity of gemcitabine (GEM) has been clinically proven in several solid tumors, including pancreatic cancer, biliary tract cancer, urinary bladder cancer, and non-small cell lung cancer. However, problems remain with issues such as acquisition of chemoresistance against GEM.